ロード中...
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
Vedolizumab is a humanized anti-α(4)β(7) integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α(4)β(7)-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely...
保存先:
| 出版年: | Clin Pharmacokinet |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5648740/ https://ncbi.nlm.nih.gov/pubmed/28523450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0546-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|